Manage haematological malignancies during pregnancy according to cancer type and gestational stage
Drugs and Therapy Perspectives, ISSN: 1179-1977, Vol: 32, Issue: 7, Page: 287-291
2016
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
Article Description
Haematological malignancies that occur during pregnancy are difficult to diagnose and manage. For patients diagnosed during trimester 1, watchful waiting or bridging therapy are options for some types of malignancies, whereas termination should be considered in patients with highly aggressive cancers that require immediate treatment with highly teratogenic agents. The use of chemotherapy is generally considered safe during trimesters 2 and 3. Special considerations should also be given to appropriate supportive care and the timing of delivery.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84975691208&origin=inward; http://dx.doi.org/10.1007/s40267-016-0303-8; http://link.springer.com/10.1007/s40267-016-0303-8; http://link.springer.com/content/pdf/10.1007/s40267-016-0303-8; http://link.springer.com/content/pdf/10.1007/s40267-016-0303-8.pdf; http://link.springer.com/article/10.1007/s40267-016-0303-8/fulltext.html; https://dx.doi.org/10.1007/s40267-016-0303-8; https://link.springer.com/article/10.1007/s40267-016-0303-8
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know